NASDAQ:DICE DICE Therapeutics (DICE) Stock Price, News & Analysis → Move Your Money Before May 1 (From Stansberry Research) (Ad) Free DICE Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$47.55▼$47.5550-Day Range$46.62▼$47.5552-Week Range$15.08▼$47.90VolumeN/AAverage Volume1.03 million shsMarket Capitalization$2.27 billionP/E RatioN/ADividend YieldN/APrice Target$55.67 Stock AnalysisStock Analysis Get DICE Therapeutics alerts: Email Address DICE Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.22 Rating ScoreUpside/Downside17.1% Upside$55.67 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.57) to ($3.44) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.05 out of 5 stars 2.1 Analyst's Opinion Consensus RatingDICE Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.22, and is based on 2 buy ratings, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageDICE Therapeutics has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for DICE. Previous Next 0.0 Dividend Strength Dividend YieldDICE Therapeutics does not currently pay a dividend.Dividend GrowthDICE Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DICE. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for DICE Therapeutics this week, compared to 1 article on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DICE Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.90% of the stock of DICE Therapeutics is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for DICE Therapeutics are expected to decrease in the coming year, from ($2.57) to ($3.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DICE Therapeutics is -20.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DICE Therapeutics is -20.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDICE Therapeutics has a P/B Ratio of 4.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About DICE Therapeutics Stock (NASDAQ:DICE)DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics. The company was founded in 2013 and is headquartered in South San Francisco, California.Read More Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. DICE Stock News HeadlinesApril 26, 2024 | finance.yahoo.comQ3 2024 Resmed Inc Earnings CallApril 3, 2024 | msn.comMinishoot' Adventures Hits Steam: A Bullet-Hell Bonanza with a Zelda TwistApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? March 8, 2024 | seekingalpha.comVoyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver EasierFebruary 24, 2024 | msn.comStoke City player ratings vs Cardiff as Potters sink into relegation zoneJanuary 31, 2024 | es-us.finanzas.yahoo.comAbercrombie Announces Official Partnership With McLaren Racing, Features Race Car in Fifth Avenue StoreJanuary 30, 2024 | msn.com15 Best Acne Treatment Products For Teens in 2024January 3, 2024 | finance.yahoo.comStar Therapeutics Appoints Scott Robertson, MBA, as Chief Business Officer and Chief Financial OfficerApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? December 30, 2023 | msn.comAltamira Therapeutics stock rises after it regains compliance with NasdaqNovember 29, 2023 | msn.comCan a Big Pharma Ever Be Worth $1 Trillion?November 4, 2023 | uk.finance.yahoo.comQ3 2023 Eli Lilly and Co Earnings CallOctober 25, 2023 | investing.comEli Lilly to buy Dice Therapeutics for $2.4 billionOctober 12, 2023 | es-us.finanzas.yahoo.comImmetas Therapeutics and GC Biopharma Announce Research Collaboration to Discover and Develop mRNA Therapeutics to Treat Autoimmune DiseasesOctober 3, 2023 | proactiveinvestors.comPoint Biopharma shares storm ahead 84% after Eli Lily's $1.4bn bidSeptember 29, 2023 | msn.comIs Eli Lilly Stock A Buy Now That It Has Topped A Profit-Taking Zone?September 11, 2023 | markets.businessinsider.comWells Fargo Sticks to Their Hold Rating for Incyte (INCY)August 9, 2023 | markets.businessinsider.comWhat 9 Analyst Ratings Have To Say About DICE TherapeuticsAugust 9, 2023 | finanznachrichten.deEli Lilly and Company: Lilly Completes Acquisition of DICE TherapeuticsAugust 9, 2023 | msn.comHC Wainwright & Co. Reiterates DICE Therapeutics (DICE) Neutral RecommendationAugust 9, 2023 | finance.yahoo.comLilly Completes Acquisition of DICE TherapeuticsAugust 8, 2023 | finanznachrichten.deEli Lilly and Company: Lilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline AdvancementsAugust 8, 2023 | markets.businessinsider.comLilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline AdvancementsJuly 25, 2023 | markets.businessinsider.comLilly Extends Tender Offer To Acquire DICEJuly 25, 2023 | finance.yahoo.comLilly Announces Extension of Tender Offer to Acquire DICEJuly 12, 2023 | msn.comDrugmakers’ deal making will plow ahead despite antitrust scrutiny, analysts sayJuly 6, 2023 | msn.comDICE Therapeutics (DICE) Price Target Decreased by 19.70% to 50.21See More Headlines Receive DICE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DICE Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:DICE CUSIPN/A CIK1645569 Webwww.dicemolecules.com Phone650-566-1420FaxN/AEmployees71Year FoundedN/APrice Target and Rating Average Stock Price Target$55.67 High Stock Price Target$71.00 Low Stock Price Target$48.00 Potential Upside/Downside+17.1%Consensus RatingHold Rating Score (0-4)2.22 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-83,890,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-22.01% Return on Assets-20.79% Debt Debt-to-Equity RatioN/A Current Ratio25.88 Quick Ratio32.44 Sales & Book Value Annual Sales$1.13 million Price / Sales2,008.50 Cash FlowN/A Price / Cash FlowN/A Book Value$10.86 per share Price / Book4.38Miscellaneous Outstanding Shares47,731,000Free Float45,392,000Market Cap$2.27 billion OptionableNot Optionable Beta1.03 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. J. Kevin Judice Ph.D. (Age 59)Founder, CEO & Director Comp: $840kMr. Scott RobertsonChief Bus. & Financial OfficerDr. Timothy Lu M.D. (Age 48)Ph.D., Chief Medical Officer Comp: $700kDr. John R. Jacobsen Ph.D. (Age 54)Chief Scientific Officer Ms. Mary Riley J.D.Gen. CounselMr. Venkat Thalladi Ph.D.Sr. VP of CMCMr. Paul FathereeSr. VP of Medicinal ChemistryMore ExecutivesKey CompetitorsTandem Diabetes CareNASDAQ:TNDMVericelNASDAQ:VCELDenali TherapeuticsNASDAQ:DNLIPrivia Health GroupNASDAQ:PRVAIntegra LifeSciencesNASDAQ:IARTView All CompetitorsInsidersNorthpond Ventures Gp, LlcSold 2,492,871 sharesTotal: $115.92 M ($46.50/share)John R JacobsenSold 18,750 sharesTotal: $572,437.50 ($30.53/share)Richard H SchellerSold 84,097 sharesTotal: $3.24 M ($38.51/share)Kevin JudiceSold 13,698 sharesTotal: $499,977.00 ($36.50/share)Scott M RobertsonSold 18,750 sharesTotal: $685,312.50 ($36.55/share) DICE Stock Analysis - Frequently Asked Questions Should I buy or sell DICE Therapeutics stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DICE Therapeutics in the last year. There are currently 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DICE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DICE, but not buy additional shares or sell existing shares. View DICE analyst ratings or view top-rated stocks. What is DICE Therapeutics' stock price target for 2024? 9 Wall Street analysts have issued twelve-month price objectives for DICE Therapeutics' stock. Their DICE share price targets range from $48.00 to $71.00. On average, they expect the company's share price to reach $55.67 in the next twelve months. This suggests a possible upside of 17.1% from the stock's current price. View analysts price targets for DICE or view top-rated stocks among Wall Street analysts. How were DICE Therapeutics' earnings last quarter? DICE Therapeutics, Inc. (NASDAQ:DICE) announced its earnings results on Friday, November, 12th. The company reported ($2.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by $1.77. When did DICE Therapeutics IPO? DICE Therapeutics (DICE) raised $160 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 10,000,000 shares at $15.00-$17.00 per share. This page (NASDAQ:DICE) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DICE Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.